Genflow Biosciences plc (GENF.L)
LSE · GBp · Healthcare · Biotechnology
£1.83 (-3.95%) as of
Key statistics
- Market cap
- 10.85M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 1.2110 – 3.1200
- Beta
- 2.27
- Revenue (TTM)
- 585.61k
- Profit margin
- -187.87%
- Volume
- 297.97k
About Genflow Biosciences plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
- Employees
- 5
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.